Novozymes A/S (OTCMKTS:NVZMY) Stock Short Interest Report for October

Key Points

• Short interest surged 1,986.3% to 11,391 shares as of October 15, up from 546 shares at the end of September. Despite the increase, short interest represented approximately 0.0% of shares outstanding, with a short-interest ratio of 0.2 days.
• Elefante Mark B increased its Novozymes stake by 73.5% during the second quarter, reaching 5,900 shares valued at approximately $371,000. Institutional investors collectively owned just 0.03% of the stock.
• NVZMY recently traded at $70.12, near its 12-month high of $75.27 and above its 50-day and 200-day moving averages. The company’s latest quarterly EPS of $0.44 missed estimates of $0.60, although revenue of $1.30 billion exceeded expectations.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 11,391 shares, a growth of 1,986.3% from the September 30th total of 546 shares. Based on an average daily volume of 47,751 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Institutional Trading of Novozymes A/S

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its position in Novozymes A/S (OTCMKTS:NVZMY - Free Report) by 73.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,900 shares of the biotechnology company's stock after purchasing an additional 2,500 shares during the quarter. Elefante Mark B's holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is currently owned by institutional investors.

Novozymes A/S Price Performance

Shares of NVZMY stock traded down $1.81 during trading hours on Monday, hitting $70.12. The company's stock had a trading volume of 14,248 shares, compared to its average volume of 26,515. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 0.25. The business has a fifty day moving average of $67.47 and a 200-day moving average of $62.46. Novozymes A/S has a twelve month low of $49.90 and a twelve month high of $75.27. The stock has a market cap of $29.07 billion, a price-to-earnings ratio of 44.38, a P/E/G ratio of 3.23 and a beta of 0.89.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last issued its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.27 billion. Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%. As a group, equities research analysts anticipate that Novozymes A/S will post 2.45 EPS for the current year.

Novozymes A/S Company Profile

Novozymes A/S was a Denmark-based biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its products were designed to help customers improve manufacturing processes, reduce resource consumption and develop more sustainable alternatives to conventional chemicals and production methods.

The company served a broad range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.